These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

615 related articles for article (PubMed ID: 28929484)

  • 1. Post-marketing research and its outcome for novel anticancer agents approved by both the FDA and EMA between 2005 and 2010: A cross-sectional study.
    Zeitoun JD; Baron G; Vivot A; Atal I; Downing NS; Ross JS; Ravaud P
    Int J Cancer; 2018 Jan; 142(2):414-423. PubMed ID: 28929484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures.
    Apolone G; Joppi R; Bertele' V; Garattini S
    Br J Cancer; 2005 Sep; 93(5):504-9. PubMed ID: 16136026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
    Salcher-Konrad M; Naci H; Davis C
    Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Qualitative Study on the Differences Between Trial Populations and the Approved Therapeutic Indications of Antineoplastic Agents by 3 Regulatory Agencies From 2010 to 2018.
    Sumi E; Asada R; Lu Y; Ito-Ihara T; Grimes KV
    Clin Ther; 2020 Feb; 42(2):305-320.e0. PubMed ID: 32008723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of the FDA Amendment Act with trial registration, publication, and outcome reporting.
    Phillips AT; Desai NR; Krumholz HM; Zou CX; Miller JE; Ross JS
    Trials; 2017 Jul; 18(1):333. PubMed ID: 28720112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Publication statuses of clinical trials supporting FDA-approved immune checkpoint inhibitors: a meta-epidemiological investigation.
    Omae K; Kataoka Y; Tsujimoto Y; Tsutsumi Y; Yamamoto Y; Fukuhara S; Furukawa TA
    BMC Cancer; 2019 Oct; 19(1):998. PubMed ID: 31651263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical trial designs to obtain marketing authorization of drugs for haematological malignancy in Japan, the EU and the US.
    Nagai S; Ozawa K
    Br J Haematol; 2016 Jul; 174(2):249-54. PubMed ID: 27018163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug approval based on randomized phase 3 trials for relapsed malignancy: analysis of oncologic drugs granted accelerated approval, publications and clinical trial databases.
    Nagai S; Ozawa K
    Invest New Drugs; 2018 Jun; 36(3):487-495. PubMed ID: 29453626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continued cancer drug approvals in Japan and Europe after market withdrawal in the United States: A comparative study of accelerated approvals.
    Hakariya H; Moriarty F; Ozaki A; Mulinari S; Saito H; Tanimoto T
    Clin Transl Sci; 2024 Jul; 17(7):e13879. PubMed ID: 38987923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring evidence on overall survival benefits of anticancer drugs approved by the European Medicines Agency between 2009 and 2015.
    Grössmann N; Robausch M; Rosian K; Wild C; Simon J
    Eur J Cancer; 2019 Mar; 110():1-7. PubMed ID: 30735832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019.
    Lythgoe MP; Desai A; Gyawali B; Savage P; Krell J; Warner JL; Khaki AR
    JAMA Netw Open; 2022 Jun; 5(6):e2216183. PubMed ID: 35687337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postmarketing studies for novel drugs approved by both the FDA and EMA between 2005 and 2010: a cross-sectional study.
    Zeitoun JD; Ross JS; Atal I; Vivot A; Downing NS; Baron G; Ravaud P
    BMJ Open; 2017 Dec; 7(12):e018587. PubMed ID: 29273664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of novel oncology drugs that received dual approval from the US accelerated approval and EU conditional marketing authorisation pathways, 2006-2021: a cross-sectional study.
    Xie J; Li J; Liu Y; Wang H; Wang Y; Yang Y; Chen Y; Jiang R; Shao R
    BMJ Open; 2023 Jun; 13(6):e069132. PubMed ID: 37286329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Review of Patient-Reported Outcomes Labeling for Oncology Drugs Approved by the FDA and the EMA (2012-2016).
    Gnanasakthy A; Barrett A; Evans E; D'Alessio D; Romano CD
    Value Health; 2019 Feb; 22(2):203-209. PubMed ID: 30711065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review of oncology and hematology drug product approvals at the US Food and Drug Administration between July 2005 and December 2007.
    Sridhara R; Johnson JR; Justice R; Keegan P; Chakravarty A; Pazdur R
    J Natl Cancer Inst; 2010 Feb; 102(4):230-43. PubMed ID: 20118413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016.
    Ladanie A; Schmitt AM; Speich B; Naudet F; Agarwal A; Pereira TV; Sclafani F; Herbrand AK; Briel M; Martin-Liberal J; Schmid T; Ewald H; Ioannidis JPA; Bucher HC; Kasenda B; Hemkens LG
    JAMA Netw Open; 2020 Nov; 3(11):e2024406. PubMed ID: 33170262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review.
    Arciero V; Delos Santos S; Koshy L; Rahmadian A; Saluja R; Everest L; Parmar A; Chan KKW
    JAMA Netw Open; 2021 Feb; 4(2):e2033004. PubMed ID: 33570573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Similarities and differences in the oncology drug approval process between FDA and European Union with emphasis on in vitro companion diagnostics.
    Senderowicz AM; Pfaff O
    Clin Cancer Res; 2014 Mar; 20(6):1445-52. PubMed ID: 24634467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delays in completion and results reporting of clinical trials under the Paediatric Regulation in the European Union: A cohort study.
    Hwang TJ; Tomasi PA; Bourgeois FT
    PLoS Med; 2018 Mar; 15(3):e1002520. PubMed ID: 29494592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals?
    Alqahtani S; Seoane-Vazquez E; Rodriguez-Monguio R; Eguale T
    Pharmacoepidemiol Drug Saf; 2015 Jul; 24(7):709-15. PubMed ID: 26013294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.